Vagus Nerve Stimulation for Depression: How It Works, Effectiveness and Current Research

Depression is usually discussed in terms of the brain, yet the systems that shape mood extend considerably further. Stress signalling, autonomic regulation, inflammation, sleep, energy metabolism and communication between the brain and internal organs all interact with neural networks involved in emotional processing, creating a physiological landscape in which mood cannot always be separated neatly from the rest of the body.

Running through many of these systems is the vagus nerve, a major communication pathway carrying information between the brainstem and organs throughout the chest and abdomen. Its unusual reach has made it an increasingly important target in neuromodulation research, including research exploring whether electrical stimulation of vagal pathways can influence depressive symptoms.

Vagus nerve stimulation for depression is already established in one highly specific clinical context: surgically implanted vagal stimulation has been used for severe treatment-resistant depression for more than two decades. More recently, researchers have begun investigating whether similar pathways can be accessed without surgery through transcutaneous vagus nerve stimulation, particularly through the auricular branch of the vagus nerve at the ear, an approach also used by technologies such as Nurosym.

The results are increasingly interesting, although understanding them requires an important distinction between established implanted VNS, emerging non-invasive approaches and the evidence belonging to individual stimulation technologies.

What Is Vagus Nerve Stimulation for Depression?

Vagus nerve stimulation, usually abbreviated to VNS, uses controlled electrical impulses to influence signalling through the vagus nerve. Although the vagus regulates many functions throughout the body, much of the therapeutic interest in VNS relates to its afferent fibres, which carry information upwards towards the brain rather than downwards towards internal organs.

Approximately 80% of vagal fibres are afferent. These sensory pathways project towards the nucleus tractus solitarius (NTS) in the brainstem, which communicates with wider networks involved in autonomic regulation, stress processing, attention, reward and mood.

That creates a biologically plausible route through which peripheral electrical stimulation can influence central nervous system activity without directly stimulating the brain itself.

There are, however, several ways to reach this pathway.

These approaches should not be treated as interchangeable. Stimulation site, waveform, frequency, intensity, treatment duration and device design can all influence the physiological response, which means that evidence generated with one method or device cannot automatically be transferred to another.

Why Is the Vagus Nerve Connected to Depression?

The relationship between vagus nerve stimulation and depression is more complex than the popular idea of simply increasing “vagal tone”. Depression is a heterogeneous condition involving multiple interacting biological, psychological and environmental mechanisms, and there is no evidence that it can be reduced to a single autonomic abnormality.

The vagus nerve is nevertheless positioned at the intersection of several systems that are relevant to depressive states.

Vagus Nerve Stimulation May Influence Mood-Related Brain Networks

When afferent vagal signals reach the NTS, they are relayed towards structures including the locus coeruleus, dorsal raphe nucleus, thalamus, amygdala and prefrontal regions, all of which participate in functions relevant to emotional regulation.

The locus coeruleus and dorsal raphe are particularly interesting because they contribute to noradrenergic and serotonergic signalling, while neuroimaging studies have shown that VNS can alter activity across cortical and limbic regions involved in mood processing. The precise antidepressant mechanism remains unresolved, but current evidence suggests that VNS acts across distributed neural networks rather than through a single neurotransmitter pathway.

VNS May Affect Stress and Autonomic Regulation

Depressive symptoms frequently coexist with altered stress responsiveness, sleep disturbance, fatigue and changes in autonomic function. Through its connections with the brainstem and hypothalamic networks, vagal signalling interacts with the hypothalamic-pituitary-adrenal axis, one of the principal systems coordinating the physiological response to stress.

This does not mean that autonomic dysregulation causes every depressive state. It does, however, help explain why researchers are interested in neuromodulation approaches capable of influencing both central emotional networks and peripheral physiological regulation.

Inflammation May Provide Another Link

A substantial body of research has also examined inflammatory signalling in subsets of people with depression. The vagus participates in neuroimmune communication, including pathways capable of influencing inflammatory activity, creating another potential mechanism through which vagal neuromodulation could interact with mood-related biology.

The importance of these mechanisms is likely to differ considerably between individuals, and they remain active areas of investigation.

What Does the Research Say About Non-Invasive Vagus Nerve Stimulation for Depression?

Non-invasive vagus nerve stimulation can be delivered through different anatomical routes, most commonly through the neck, known as transcutaneous cervical VNS, or through the outer ear, known as transcutaneous auricular VNS (taVNS). For depression, much of the emerging research has focused on the auricular approach, which accesses the auricular branch of the vagus nerve through the skin of the ear without surgery.

The evidence is becoming increasingly compelling. A 2023 meta-analysis bringing together 12 randomised studies and 838 participants found that taVNS was associated with improvements in depression scores and a greater likelihood of response than sham stimulation.

More recently, a 2026 randomised study in people with major depressive disorder reported encouraging results after eight weeks of auricular stimulation. Among participants receiving active taVNS, 62.5% met the study criteria for response and 35% reached remission, compared with 30% and 2.5% respectively in the sham group.

In clinical research, response generally describes a substantial reduction in symptoms, while remission means symptoms have fallen below a defined clinical threshold. There is therefore no single vagus nerve stimulation depression success rate, but these findings add to a growing body of evidence suggesting that repeated auricular stimulation can meaningfully influence depressive symptoms.

Crucially, auricular VNS is not one uniform intervention. Electrode placement, waveform, frequency, intensity and stimulation schedule all affect how vagal pathways are engaged, making evidence generated with a defined technology more informative than broad claims about VNS as a category.

This distinction is particularly relevant to Nurosym, which uses Parasym's AVNT™ technology to deliver controlled, repeatable stimulation at the tragus, an area supplied by the auricular branch of the vagus nerve. Its own research programme has also examined mood-related outcomes, which we explore below.

How Long Does Non-Invasive Vagus Nerve Stimulation Take to Work?

Vagus nerve stimulation is better understood as repeated neuromodulation rather than an instant calming technique.

Studies examining depressive symptoms have generally used regular stimulation over several weeks, with many protocols lasting around four to eight weeks. This fits with the broader understanding of neuromodulation: repeated vagal input may gradually influence networks involved in emotional regulation, stress signalling and neuroplasticity rather than producing its full effect during a single session.

For people considering a wearable approach such as Nurosym, this distinction matters. The technology is designed for structured, repeatable daily stimulation, reflecting the way non-invasive VNS has generally been investigated in clinical research rather than positioning stimulation as a one-off “reset”.

What Does Nurosym-Specific Research Show About Depressive States?

The broader taVNS literature establishes the scientific rationale for stimulating the auricular branch of the vagus nerve, but device-specific evidence remains important because stimulation parameters and delivery systems differ.

Nurosym uses Parasym's Auricular Vagal Neuromodulation Technology, AVNT™, delivering controlled electrical stimulation at the tragus of the ear. The technology is designed for structured, repeatable daily use and has been investigated across autonomic, cardiovascular, inflammatory, cognitive, sleep and post-viral research.

In a 2024 published pilot study of female participants with persistent post-viral symptoms used the Parasym AVNT system at home for ten consecutive days, with two 30-minute sessions each day. Depression was measured using the Beck Depression Inventory-II alongside anxiety, sleep, fatigue and cognition.

Depression scores improved significantly immediately following the intervention and remained significantly improved at one-month follow-up. 

An earlier Parasym pilot involving people with persistent post-viral symptoms reported an approximately 45% reduction in depressive-state scores over the study period. 

Nurosym's broader research programme includes more than 10 years of research and development, 60+ completed clinical studies, 100+ ongoing studies, 150+ research partners and more than 5 million user sessions.

Across this research programme, AVNT™ has produced measurable changes across several areas closely connected with mood and nervous-system regulation, with some of the most notable findings summarised below.

Anxious Thoughts Reduced by 35%

In AVNT™ research, anxious-thought scores decreased by approximately 35% in the study population.

Anxious thoughts and low mood often overlap, particularly where persistent worry, heightened arousal and difficulty disengaging from negative thought patterns are present. Although they are distinct experiences, improvement across both domains may point towards a broader effect on the neural and autonomic systems involved in emotional regulation.

Fatigue Reduced by 48%

Persistent fatigue improved by approximately 48% in AVNT™ research.

Fatigue is frequently intertwined with depressive states, affecting motivation, concentration and the ability to engage with everyday activity. While it is not itself a measure of depression, improvement in energy can meaningfully shape day-to-day functioning and adds important context to the mood-related findings.

Brain Fog Reduced by 40%

AVNT™ research has also reported an approximately 40% reduction in brain fog within the study population.

Difficulty concentrating, slowed thinking and reduced mental clarity can accompany periods of low mood, making cognitive function an important part of the wider picture. Improvements in brain fog therefore add useful context when considered alongside changes in depressive states, anxious thoughts and fatigue.

Gastrointestinal Symptoms Improved by Around 80%

In one AVNT™ study, gastrointestinal symptoms improved by approximately 80% as a secondary outcome.

The vagus nerve forms a major communication pathway between the brain and gastrointestinal system, and this brain-gut relationship is increasingly studied in relation to emotional as well as digestive function. Although gastrointestinal improvement is not a direct measure of depressive symptoms, it adds to the broader picture of how vagal neuromodulation may influence interconnected autonomic systems.

Autonomic Activity Increased by 61%

The mood-related findings are also supported by research examining objective physiological markers of autonomic regulation.

In placebo-controlled research using Parasym's technology, high-frequency HRV power, a measure influenced by cardiac parasympathetic activity, increased by 61%.

This is not a direct measure of depression, however, its relevance lies in demonstrating measurable effects within autonomic pathways involved in stress regulation and physiological recovery.

Taken together, these findings suggest that AVNT™ research extends beyond low mood alone. Depressive states, anxious thoughts, fatigue, cognitive clarity, gastrointestinal symptoms and objective autonomic measures have all been investigated, providing a broader physiological context for understanding how vagal neuromodulation may influence systems associated with mood regulation.

Is Non-Invasive Vagus Nerve Stimulation Safe?

Avoiding surgery changes the safety profile considerably.

Implanted VNS requires an operation to place the generator and electrodes, while stimulation can produce recognised effects including voice alteration, coughing, throat sensations and breathing-related symptoms. These considerations are part of the reason implanted VNS is generally reserved for highly treatment-resistant cases.

Transcutaneous auricular stimulation avoids implantation. A systematic review examining 177 taVNS studies and more than 6,300 participants found no significant difference in the risk of adverse events between active stimulation and control conditions; the most commonly reported effects were ear discomfort, headache and tingling, while the review identified no causal association between taVNS and serious adverse events. 

Nurosym also has device-specific safety data. A pooled analysis covering over 200 cardiovascular patients across seven studies reported no device-related serious adverse events to date, with only three participants experiencing minor effects described as brief tingling at the ear.

Individual suitability still matters, particularly for people with implanted electrical devices, significant cardiovascular conditions or other circumstances covered by the device contraindications. As safety has not been established across all populations, Nurosym is not recommended for children or during pregnancy.

Can Vagus Nerve Stimulation Help With Depression?

There is now credible evidence that stimulating vagal pathways can influence neural systems involved in depressive symptoms, and vagus nerve stimulation in depression has progressed from an experimental observation to a substantial field of psychiatric neuromodulation research.

Implanted VNS has the longest clinical history and is used in selected people with severe treatment-resistant depression, although its invasive nature and mixed trial findings mean that it remains a specialist intervention. Non-invasive auricular VNS offers a fundamentally different route, reaching vagal afferent pathways through the outer ear without surgery, and recent randomised studies provide encouraging evidence that this approach can help reduce depression scores in some populations.

Nurosym contributes to this emerging field through a device-specific AVNT™ research programme in which improvements in depressive states have been observed alongside changes in anxiety, sleep, fatigue, cognition and autonomic function. For somebody interested in non-invasive vagus nerve stimulation device, that evidence provides a considerably more meaningful foundation than relying on the broad claim that all forms of “VNS” work in the same way.

Vagal neuromodulation is therefore becoming an increasingly credible part of the wider conversation around mood and nervous-system regulation, while remaining an area in which careful distinctions between promising research, established clinical treatment and device-specific evidence continue to matter.

Disclaimer: Nurosym is a CE-marked medical device in Europe. The clinical research referenced in this article was conducted using Parasym’s neuromodulation technology under research conditions, some of which include populations outside of the device’s primary indication. Individual results may vary. All percentage figures cited reflect findings from specific study populations and should not be interpreted as a medical claim, and cannot guarantee outcomes for all users. Individuals should consult a qualified health professional regarding their personal health needs.

References:

1. Dalle Luche R, et al. First report of safety and tolerability of low-level tragus vagal neuromodulation in cardiovascular patients. J Am Coll Cardiol. 2024.

2. Geng Y, et al. Circadian stage-dependent and stimulation duration effects of transcutaneous auricular vagus nerve stimulation on heart rate variability. PLoS One. 2022.

3. Maestri R, et al. Impact of optimized transcutaneous auricular vagus nerve stimulation on cardiac autonomic profile in healthy subjects and heart failure patients. Physiol Meas. 2024.

4. Molaeizadeh G, et al. Effects of transcutaneous vagus nerve stimulation, neurofeedback, and their combination on cortisol, anxiety, and depression subtypes in non-clinical adults. 2025.

5. Stavrakis S, et al. TREAT AF — transcutaneous electrical vagus nerve stimulation to suppress atrial fibrillation: a randomised clinical trial. JACC Clin Electrophysiol. 2020.

6. Stavrakis S, et al. Noninvasive vagus nerve stimulation in postural tachycardia syndrome: a randomized clinical trial. JACC Clin Electrophysiol. 2023.

7. Dasari TW, et al. Effects of low-level tragus stimulation on endothelial function in heart failure with reduced ejection fraction. J Card Fail. 2021;27(5).

8. Dasari TW, et al. Noninvasive low-level tragus stimulation attenuates inflammation and oxidative stress in acute heart failure. Clin Auton Res. 2023.

9. Mbikyo E, et al. Low-level tragus stimulation attenuates blood pressure in young individuals with hypertension: results from a small-scale single-blind controlled randomized clinical trial. J Am Heart Assoc. 2024.

10. Zheng Y, et al. Transcutaneous vagus nerve stimulation improves Long COVID symptoms in a female cohort: a pilot study. Front Neurol. 2024.

11. Verbanck P, et al. Transcutaneous auricular vagus nerve stimulation (tVNS) can reverse the manifestations of the Long-COVID syndrome: a pilot study. Adv Neurol Neurosci Res. 2021.

12. Natelson B, Blate M, Soto T. Transcutaneous vagus nerve stimulation for long COVID and chronic fatigue symptoms. medRxiv. 2022.

13. Dolcini J, et al. Vagal nerve stimulation and fibromyalgia: an additional therapeutic option. Clin Exp Rheumatol. 2025.

14. Jackowska M, et al. Effects of transcutaneous vagus nerve stimulation on subthreshold affective symptoms and perceived stress: findings from a single-blinded randomized trial in community-dwelling adults. 2025.

15. Kamboj SK, et al. Electroceutical enhancement of self-compassion training using transcutaneous vagus nerve stimulation: results from a preregistered fully factorial randomized controlled trial. Psychol Med. 2025.

 

Zurück zum Blog